Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2015

View Archived Issues

Prevention of HIV transcription from latency by Tat inhibitor

BioRestorative Therapies to evaluate encapsulation technology for use in metabolic program

Dauntless Pharmaceuticals closes series A financing, licenses technology from Aegis

KalVista Pharmaceuticals raises funds to advance plasma kallikrein inhibitor pipeline

Merck & Co.'s Keytruda approved in Europe for advanced melanoma

Novartis presents milestones of second quarter 2015

Discovery and optimization of a pan-RET/VEGFR-2 dual inhibitor for single-agent polypharmacology

New organotypic brain slice culture model helps elucidate Alzheimer's disease pathology

Horizon Pharma increases share offer for Depomed

CNGA2 KO mice show AD-like pathological features

Beaufour Ipsen Tianjin Pharmaceutical describes AR degraders

Intra-Cellular Therapies plans phase III program for ITI-007 in bipolar depression

Polyphor reports selective elastase inhibitors

Catalyst initiates rolling NDA for Firdapse in LEMS

West China Hospital, Sichuan University reports short-acting anesthesic

Novartis files sBLA for ofatumumab as maintenance therapy for relapsed CLL

Alectos Therapeutics designs GCase inhibitors

Erum Biotechnologies patents PTP-1B inhibitors

Vidasym's phosphate binder VS-505 enters phase I/II trial

Phase I study investigates T4 immunotherapy for head and neck cancer

Xoma reports data from phase III EYEGUARD-B study

Roche Diagnostics launches HTLV blood test

AMAG Pharmaceuticals obtains option to acquire digoxin immune fab for pre-eclampsia

NIH funds collaborative project to develop measures of social impairment in autism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...